St Vincent's University Hospital
- Address
- Elm Park Merrion Road, D04 T6F4 Dublin, Ireland
Diseases and Nutritional and Metabolic Diseases
The Clinical Research Centre at St Vincent's University Hospital is conducting studies focused on obesity and related metabolic health concerns. This research area explores new ways to improve weight management and understand broader health risks linked to excess body weight.
- Evaluating new therapies for overweight and obesity
- Assessing cardiovascular safety in people with metabolic disease
- Studying whether emerging treatments can improve long-term health outcomes
These trials are designed to test the effectiveness and safety of potential treatments, with a particular interest in reducing serious health complications associated with obesity.
Cardiometabolic Research
Clinical research at this site also examines how treatments for obesity may affect major cardiovascular outcomes. The work is aimed at understanding whether new options can support both weight-related care and protection against heart and blood vessel complications.
- Investigating prevention of cardiovascular events in people with obesity
- Comparing treatment effects on serious outcomes such as stroke and myocardial infarction
- Supporting safer, more effective care for patients with metabolic disease
With a small but focused portfolio, St Vincent's University Hospital is contributing to research that may improve both metabolic health and long-term cardiovascular safety.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 3 of 16 therapeutic areas and 15 of 215 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 199 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 36 by active trials.
- 1Merck Sharp & Dohme LLC8active
lock +35 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC14trials
lock +19 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in St Vincent's University Hospital
lock Showing 1 of 106 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Multicenter, Open-label, Phase 3 Study to Evaluate the Long-term Safety and Efficacy in Participants who are Currently on Treatment or in Follow-up in Studies That Include Pembrolizumab | Merck Sharp & Dohme LLC | Phase III | Recruiting | Aug 2018 | — |
IMP list
lock Showing 1 of 215 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 11 | Unknown | 2017-03-07 | 2025-09-18 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.